1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NHLBI Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) Programs is sponsored by National Heart, Lung, and Blood Institute (NHLBI/NIH). The NHLBI supports SBIR/STTR activities that advance the prevention, diagnosis, and treatment of heart, lung, blood, and sleep disorders.
These programs enable US-owned and operated small businesses to conduct research and development with strong potential for commercialization.
Get alerted about grants like this
Get emailed when new opportunities from “National Heart, Lung, and Blood Institute (NHLBI/NIH)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NHLBI Small Business Program | NHLBI, NIH NHLBI Small Business Program NHLBI Small Business Program The NHLBI is interested in Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) activities that advance the prevention, diagnosis, and treatment of heart, lung, blood, and sleep disorders.
Below is a list of funding opportunity announcements that offer small business entrepreneurs a chance to obtain funding without requirements to give up equity or ownership for early-stage research and development. Get answers to frequently asked questions about the NHLBI Small Business Program .
Learn more about the Innovation and Commercialization Office (I&C) , which coordinates the institute’s Small Business Program, offers services to SBIR/STTR applicants and awardees, provides digital education and online resources, and supports other SBIR/STTR awardee opportunities. Small Business Program Coordinator Julia Berzhanskaya, Ph. D.
NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) PHS 2024-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed) SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required) Notice of Special Interest (NOSI): Small Business Initiatives for Innovative tools and Technologies for Improving Outcomes for Maternal Health Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Not Allowed) Small Business Transition Grant for New Entrepreneurs (R43/R44 Clinical Trial Required) Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Not Allowed) Small Business Transition Grant for New Entrepreneurs (R41/R42 Clinical Trial Required) Notice of NHLBI Participation in NOT-AI-24-007 "Notice of Special Interest (NOSI): RNA Delivery Technologies to Allow Specific Tissue Target Homing (RNA-DASH)" Notice of Special Interest (NOSI): Translating Biomaterials-Based Technologies to Commercially Viable Products Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence/Machine Learning Tools for Improved Assessment in Biomedical and Behavioral Research Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health Notice of Special Interest: Womens Health Research Notice of Special Interest (NOSI): Development of Functional Assay Sites to Evaluate Candidate -Omics Variants Associated with Heart, Lung, Blood, or Sleep Disease (R01, R41, R42, R43, R44) Innovation and Commercialization Office NHLBI's Small Business Program Frequently Asked Questions Small Business and Academic Innovation Success Stories NIH's Small Business Education and Entrepreneurial Development (SEED) website Innovation and Commercialization Office Inquiry Form
According to the current listing, eligibility includes: Eligible United States small business concerns (SBCs). Small business applicants interested in submitting an STTR grant application should submit to PAR-24-133. Confirm the full requirements in the official notice before applying.
The current listing shows varies by phase and institute, but NHLBI applies a strict cap of $500,000 for some awards. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for NHLBI Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) Programs are due September 8, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NHLBI Small Business Innovation Research (SBIR) & Small Business Technology Transfer (STTR) Programs is funded by National Heart, Lung, and Blood Institute (NHLBI/NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NHLBI Program Project Applications (P01 Clinical Trials Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI/NIH). The NHLBI Program Project Grant (P01) supports large-scale, investigator-initiated research programs addressing fundamental processes and diseases of the heart, blood vessels, lungs, and blood, including transfusion medicine, blood resources, and sleep disorders.
NHLBI Program Project Grants (P01 Clinical Trials Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI/NIH). This funding opportunity supports large-scale, investigator-initiated research programs that address scientific areas relevant to the NHLBI mission, including the biology and diseases of the heart, blood vessels, lung, and blood; blood resources; and sleep disorders.
NHLBI Program Project Grants (P01) is sponsored by National Heart, Lung, and Blood Institute (NHLBI/NIH). NHLBI Program Project Grants (P01) is a funding opportunity from the National Heart, Lung, and Blood Institute (NHLBI/NIH) that supports large-scale, investigator-initiated research programs addressing heart, blood vessel, lung, blood, and sleep disorder biology and disease.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
After a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read articleNIH's FY2026 budget held steady at $47.2 billion — yet by the end of February the agency had issued roughly 66% fewer competitive grant awards than its FY21–24 average, and by late spring award volume was still running dramatically below historical norms. The cause is not a budget cut. It is a pipeline failure: only 14 Notices of Funding Opportunity published by mid-March versus 756 in all of 2024, a workforce down nearly 20%, funds held by OMB into March, and new political-appointee sign-off on NOFOs. FY25 success rates fell to 17% — the lowest in 30 years — and early-stage investigators dropped to 18.5%. This is the definitive breakdown of what is happening, why the money isn't moving, and the concrete diversification strategy labs need for the next 18 months.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read article